CANDEL THERAPEUTICS, INC. Other General and Administrative Expense
CANDEL THERAPEUTICS, INC. (CADL) reported Other General and Administrative Expense of $653.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OtherGeneralAndAdministrativeExpense · last filed 2026-08-13
- CANDEL THERAPEUTICS, INC. other general and administrative expense for the quarter ending 2026-06-30 was $653.00K, a 41.34% increase year-over-year.
- CANDEL THERAPEUTICS, INC. other general and administrative expense for the quarter ending 2026-03-31 was $691.00K, a 48.92% increase year-over-year.
- CANDEL THERAPEUTICS, INC. other general and administrative expense for the quarter ending 2025-12-31 was $479.00K, a 2.24% decline year-over-year.
- CANDEL THERAPEUTICS, INC. other general and administrative expense for the quarter ending 2025-09-30 was $443.00K, a 4.32% decline year-over-year.
- CANDEL THERAPEUTICS, INC. other general and administrative expense for fiscal 2025 was $1.85M, a 5.86% decline from fiscal 2024.
- CANDEL THERAPEUTICS, INC. other general and administrative expense for fiscal 2024 was $1.96M, a 25.81% decline from fiscal 2023.
- CANDEL THERAPEUTICS, INC. other general and administrative expense for fiscal 2023 was $2.65M.
| Period end | Other General and Administrative Expense 3 month | Other General and Administrative Expense 6 month | Other General and Administrative Expense 9 month | Other General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $653.00K 10-Q · filed 2026-08-13 | $1.34M 10-Q · filed 2026-08-13 | $1.82M derived: sum of 3 quarters · filed 2026-08-13 | $2.27M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $691.00K 10-Q · filed 2026-05-14 | $1.17M derived: sum of 2 quarters · filed 2026-05-14 | $1.61M derived: sum of 3 quarters · filed 2026-05-14 | $2.08M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $479.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $922.00K derived: sum of 2 quarters · filed 2026-03-12 | $1.38M derived: sum of 3 quarters · filed 2026-08-13 | $1.85M 10-K · filed 2026-03-12 |
| 2025-09-30 | $443.00K 10-Q · filed 2025-11-13 | $905.00K derived: sum of 2 quarters · filed 2026-08-13 | $1.37M 10-Q · filed 2025-11-13 | $1.86M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $462.00K 10-Q · filed 2026-08-13 | $926.00K 10-Q · filed 2026-08-13 | $1.42M derived: sum of 3 quarters · filed 2026-08-13 | $1.88M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $464.00K 10-Q · filed 2026-05-14 | $954.00K derived: sum of 2 quarters · filed 2026-05-14 | $1.42M derived: sum of 3 quarters · filed 2026-05-14 | $1.93M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $490.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $953.00K derived: sum of 2 quarters · filed 2026-03-12 | $1.47M derived: sum of 3 quarters · filed 2026-03-12 | $1.96M 10-K · filed 2026-03-12 |
| 2024-09-30 | $463.00K 10-Q · filed 2025-11-13 | $980.00K derived: sum of 2 quarters · filed 2025-11-13 | $1.47M 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $517.00K 10-Q · filed 2025-08-14 | $1.01M 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | $493.00K 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | $2.65M 10-K · filed 2025-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |